Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Director comp.
|
|
NUPATHE INC. (PATH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/14/2013 |
8-K
| Quarterly results |
| 08/08/2013 |
8-K
| Quarterly results |
| 08/14/2012 |
8-K
| Quarterly results |
| 03/20/2012 |
8-K
| Quarterly results |
| 11/14/2011 |
8-K
| Form 8-K - Current report |
| 08/15/2011 |
8-K
| Quarterly results |
| 05/10/2011 |
8-K
| Quarterly results |
| 03/18/2011 |
8-K
| Form 8-K - Current report |
| 11/12/2010 |
8-K
| Quarterly results |
| 09/14/2010 |
8-K
| Quarterly results|
Docs:
|
"NuPathe Inc. Reports Second Quarter 2010 Results CONSHOHOCKEN, PA — September 14, 2010 — NuPathe Inc. , a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announced financial results for the quarter ended June 30, 2010. The Company completed its initial public offering on August 11, 2010, after the end of the second quarter. “With the completion of our IPO in August 2010, we are pleased to report quarterly results for the first time as a public company,” said Jane H. Hollingsworth, chief executive officer. “With the addition of the net proceeds from the IPO, we believe we now have the financial strength necessary to focus on our primar..." |
|
|
|